A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T- cell consortium trial

Ranjana H. Advani*, Stephen M. Ansell, Mary J. Lechowicz, Anne W. Beaven, Fausto Loberiza, Kenneth R. Carson, Andrew M. Evens, Francine Foss, Steven Horwitz, Barbara Pro, Lauren C. Pinter-Brown, Sonali M. Smith, Andrei R. Shustov, Kerry J. Savage, Julie M. Vose

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T- cell consortium trial'. Together they form a unique fingerprint.

Medicine & Life Sciences